For a list of publications please click here (Pubmed) or here (Google Scholar). 

Highlighted Research Publications

• O. Efthimiou / H. Taipale / J. Radua / J. Schneider-Thoma / J. Pinzón-Espinosa / M. Ortuño, …, & J.J. Luykx. Efficacy and Effectiveness of Antipsychotics in Schizophrenia: Combining Evidence from Randomised Controlled Trials and Real-World Data (The Lancet Psychiatry, in press): we found a way to combine RCT and real-world data on the efficacy and effectiveness of antipsychotics and then ran joint analyses, revealing insights into how RCT-findings generalize to real-world settings, e.g. we find that relative effects of antipsychotics largely agree between the two settings but that long-acting injectables are more effective relative to their oral counterparts only in the real-world. 

• B. Lin / J. Pinzón-Espinosa, ..., & J.J. Luykx. Associations between polygenic loading, psychosis liability and clozapine us (JAMA Psychiatry, 2023): leveraging rich phenotypic and genotypic data from several cohorts we demonstrate how polygenic risk scores vary according to a psychosis liability spectrum and may be predictive of future clozapine use.

• B. Lin, …, & J.J. Luykx. Associations between genetic liabilities to smoking behavior andschizophrenia symptoms in patients with a psychotic disorder, their siblingsand healthy controls (Psychiatry Research, 2023): we show howsmoking behavior polygenic liabilities differentially associate with symptomlevels across patients, siblings and healthy controls.

• H. Taipale / J. Thoma-Schneider / J. Pinzón-Espinosa, …, & J.J. Luykx. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials (JAMA Psychiatry, 2022): we found a way to analyze real-world representation of schizophrenia patients eligible for RCTs, which turned out to be only around 20%, leading us to call for more inclusive RCTs.

• J.J. Luykx / D. Loef / B. Lin, …& A. Dols / B. Rutten. Interrogating Associations between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness (Biological Psychiatry, 2022): I united collaborators over Europe to collect the largest ECT responsiveness dataset with DNA to date and found a strong and linear, consistent association between PRS-schizophrenia and ECT responsiveness. 

• Okhuijsen-Pfeifer / M. van der Horst / B. Lin / C. Bousman, …. & J.J. Luykx. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder (Translational Psychiatry, 2022): using data collected in a large consortium led by myself, CLOZIN, we demonstrate that high polygenic risk scores for schizophrenia are associated with lower burden of symptoms in patients with schizophrenia who are using clozapine. 

• M. Olislagers, K. Rademakers, R. Adan, B. Lin & J.J. Luykx. Comprehensive analyses of RNA-seq and genome-wide data point to enrichment of neuronal cell type subsets in neuropsychiatric disorders (Molecular Psychiatry, 2022): using available genetic data of millions of people we show that neuronal subsets are consistently implicated in psychiatric disorders while in neurological disorders a variety of CNS cells are involved.

• N. de Boer, …& J.J. Luykx. Longitudinal associations between alcohol use, smoking, genetic risk scoring, and symptoms of depression in the general population: a prospective six-year cohort study (Psychological Medicine, 2021): with collaborators from TRIMBOS in a longitudinal cohort with phenotypic and genotype data we show that reducing smoking and alcohol use diminishes depressive symptoms later on.

• J.J. Luykx & B. Lin. Are psychiatric disorders risk factors for COVID-19 susceptibility and severity? a two-sample, bidirectional, univariable and multivariable Mendelian Randomization study (Translational Psychiatry, 2021): using large genetic datasets we show it’s unlikely that psychiatric disorders increase COVID-19 risk. 

• J.J. Luykx, N. Stam, …. & Heidi Taipale. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients stopping clozapine (British Journal of Psychiatry, 2020): with Finnish collaborators we show that in those stopping clozapine for unknown reasons restarting clozapine and olanzapine are safest and most effective. 

• B.D. Lin, A. Alkema, …. & J.J. Luykx. Assessing causal links between metabolic traits, inflammation and schizophrenia: a univariable and multivariable bidirectional Mendelian Randomization study (International Journal of Epidemiology, 2019): using both univariate and multivariate MR we find evidence that dyslipidemia has a role in schizophrenia independent of medication status. 

• R. McLaughlin, D. Schijven,….. & O. Hardiman / J.H. Veldink / J.J. Luykx. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia (Nature Communications, 2017): in an international consortium set up by others and myself we found the first evidence of genetic overlap between schizophrenia and ALS.  

Highlighted Collaborative Work

·      V. Trubetskoy, …, J.J. Luykx, et al. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia (Nature, 2022).

·      L.. Katrin-Pries, …, J.J. Luykx, B. Rutten & S. Guloksuz. The main and interacting effects of recent stressful life events with genomic and exposomic liability for schizophrenia on mental and physical health (JAMA Psychiatry, 2020).

·      K. Gatsby, …., J.J. Luykx, et al. The Genetic Architecture of the HumanCerebral Cortex (Science, 2020).

·      S. Guloksuz, …, J.J. Luykx, B. Rutten & J. van Os. Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort (World Psychiatry, 2020).

·      Cross-disorder group of the psychiatric genomics consortium, …., J.J. Luykx, et al. Genome-wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders (Cell, 2019).

·      L. Duncan, …., J.J. Luykx, et al. Anorexia nervosa genome-wide association study identifies eight loci implicating metabo-psychiatric origins (Nature Genetics, 2019).

Highlighted Review Papers

·         J.J. Luykx / J. Gonzalez, …, & J. Tiihonen. An international research agendafor clozapine-resistant schizophrenia (Lancet Psychiatry, 2023): with a group of experts, such as clinician-scientists, experienced experts, and family members from across the globe we highlight unmet needs in the treatment of difficult-to-treat psychosis and propose an international research agenda to improve outcomes of people with such conditions..

·      J. Pinzón-Espinosa / M. van der Horst, …., & J.J.Luykx. Barriers to genetic testing in clinical psychiatry andways to overcome them: from clinicians’ attitudes to sociocultural differencesbetween patients across the globe (Translational Psychiatry, 2022): we discussbarriers to genetic testing and ways to overcome them to ensure patients mayreceive genetic testing in psychiatry when needed.

·      E. Eeltink, …, & J.J. Luykx. Polygenic risk Sscores for genetic counselingin psychiatry: lessons learned from other fields of medicine (Neuroscience& Biobehavioral Reviews, 2021): in this systematic review weshow how clinical psychiatry may benefit from applying polygenic scoring tocertain diagnostic and therapeutic dilemmas and how the field of psychiatry maylearn from experiences in other fields, such as Alzheimer’s dementia.

·    C. Okhuijsen-Pfeifer, …,& J.J. Luykx. Demographicand clinical features as predictors of clozapine response in patients withschizophrenia spectrum disorders: a systematic review and meta-analysis (Neuroscience& Biobehavioral Reviews, 2020).

·      D. Schijven,J.H. Veldink & J.J. Luykx. Genetic cross-disorder analysis in psychiatry: from methodology toclinical utility (British Journal ofPsychiatry, 2020): in thispaper we discuss the ramifications and clinical implications of geneticcross-disorder research for patients and psychiatrists.

Highlighted opinion pieces, editorials and viewpoints

·       J.J.Luykx& Helena Voetterl. Towards ecologically sustainable mental healthcare: a call for actionfrom within psychiatry (JAMA Psychiatry, 2022).

·       J.J. Luykx. Psychiatric organizations shouldunite voices in condemning the invasion of Ukraine (Lancet Psychiatry, 2022).

·       J.J.Luykx& Jari Tiihonen. Antipsychoticdiscontinuation: mind the patient and the real-world evidence (Lancet Psychiatry,2021).

·       J.J.Luykx,C.H. Vinkers & J.K. Tijdink. Psychiatry in times of the COVID-19 pandemic: an imperative forpsychiatrists to act now (JAMA Psychiatry, 2020).

·       J.J. Luykx, … & C.H. Vinkers. Safe andinformed prescribing of psychotropic medication during the COVID-19 pandemic (BritishJournal of Psychiatry, 2020).

·       J.J. Luykx, A. Di Florio & VeerleBergink. Prevention of infanticide and suicide in the postpartum period: theimportance of emergency care (JAMA Psychiatry, 2019).

·       J.J. Luykx, R. van der Spek, …., Annelien Bredenoord &Ger Palmboom. Unconsentedgenetic testing in psychiatry: an (almost) no go? (Lancet Psychiatry, 2019).

·       B. Lin, Y. Li & J.J. Luykx.Mendelian Randomization concerns (JAMAPsychiatry, 2018).